EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Regulatory Network of hnRNPs Underlying Regulating PKM Alternative Splicing in Tumor Progression

Yuchao Li, Shuwei Zhang, Yuexian Li, Junchao Liu, Qian Li, Wenli Zang, Yaping Pan

Biomolecules · 09.05.2024 · 14 (5) · 566

DOI: 10.3390/biom14050566 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 09.05.2024. Verfasst von Yuchao Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Liaoning Provincial Key Laboratory of Oral Diseases, School and Hospital of Stomatology, China Medical University, Shenyang 110002, China. Hauptthemen laut MEDLINE: Alternative Splicing, Neoplasms, Heterogeneous-Nuclear Ribonucleoproteins, Pyruvate Kinase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the hallmarks of cancer is metabolic reprogramming in tumor cells, and aerobic glycolysis is the primary mechanism by which glucose is quickly transformed into lactate. As one of the primary rate-limiting enzymes, pyruvate kinase (PK) M is engaged in the last phase of aerobic glycolysis. Alternative splicing is a crucial mechanism for protein diversity, and it promotes PKM precursor mRNA splicing to produce PKM2 dominance, resulting in low PKM1 expression. Specific splicing isoforms are produced in various tissues or illness situations, and the post-translational modifications are linked to numerous disorders, including cancers. hnRNPs are one of the main components of the splicing factor families. However, there have been no comprehensive studies on hnRNPs regulating PKM alternative splicing. Therefore, this review focuses on the regulatory network of hnRNPs on PKM pre-mRNA alternative splicing in tumors and clinical drug research. We elucidate the role of alternative splicing in tumor progression, prognosis, and the potential mechanism of abnormal RNA splicing. We also summarize the drug targets retarding tumorous splicing events, which may be critical to improving the specificity and effectiveness of current therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alternative SplicingNeoplasmsHeterogeneous-Nuclear RibonucleoproteinsPyruvate KinaseHumansDisease ProgressionGene Expression Regulation, NeoplasticAnimals

Stichwörter der Autor:innen

PKM1PKM2alternative splicingglycolysishnRNPs

Substanzen

Heterogeneous-Nuclear RibonucleoproteinsPyruvate Kinase

Autor:innen und Institutionen

  • Liaoning Provincial Key Laboratory of Oral Diseases, School and Hospital of Stomatology, China Medical University, Shenyang 110002, China.
  • Department of Radiation Oncology Gastrointestinal and Urinary and Musculoskeletal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang 110042, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, Y., Zhang, S., Li, Y., Liu, J., Li, Q., Zang, W., & Pan, Y. (2024). The Regulatory Network of hnRNPs Underlying Regulating PKM Alternative Splicing in Tumor Progression. Biomolecules, 14(5), 566. https://doi.org/10.3390/biom14050566

Vancouver

Li Y, Zhang S, Li Y, Liu J, Li Q, Zang W, et al. The Regulatory Network of hnRNPs Underlying Regulating PKM Alternative Splicing in Tumor Progression. Biomolecules. 2024;14(5):566. doi:10.3390/biom14050566

BibTeX
@article{Li2024,
  author = {Li, Yuchao and Zhang, Shuwei and Li, Yuexian and Liu, Junchao and Li, Qian and Zang, Wenli and Pan, Yaping},
  title = {The Regulatory Network of hnRNPs Underlying Regulating PKM Alternative Splicing in Tumor Progression},
  journal = {Biomolecules},
  year = {2024},
  volume = {14},
  number = {5},
  pages = {566},
  doi = {10.3390/biom14050566}
}
Kostenlos starten →